imiquimod has been researched along with astilbin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di, TT; Li, P; Liu, X; Ruan, ZT; Wang, Y; Zhao, JX | 1 |
| Cao, G; Cao, Z; Liu, Z; Shi, Y; Sun, R; Xu, Q; Yang, N; Zhang, C | 1 |
2 other study(ies) available for imiquimod and astilbin
| Article | Year |
|---|---|
Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway.
Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents; Cell Differentiation; Cell Proliferation; Flavonols; Imiquimod; Immunologic Factors; Interleukin-17; Janus Kinase 3; Keratinocytes; Male; Mice, Inbred BALB C; Psoriasis; Signal Transduction; Skin; STAT3 Transcription Factor; Th17 Cells | 2016 |
Topical astilbin ameliorates imiquimod-induced psoriasis-like skin lesions in SKH-1 mice via suppression dendritic cell-Th17 inflammation axis.
Topics: Animals; Cytokines; Dendritic Cells; Disease Models, Animal; Flavonols; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2022 |